Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesi...
Elevai Labs, Inc. (ELAB)
Company Research
Source: GlobeNewswire
Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.Elevai believes that EL-32 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to conduct additional animal studies to advance EL-32 towards an Investigational New Drug (IND) application. NEWPORT BEACH, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Elevai Biosciences Inc. (“Elevai Biosciences”), a subsidiary of Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), today released encouraging past preclinical data from 2022 for EL-32, a pioneering dual-action blocker targeting myostatin and activin-A. Preclinical results generated from our licensing partner in a 2022 study indicated that EL-32 may offer a breakthrough approach to obesity treatment by simultaneously preserving muscle mass
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- CORRECTION - Elevai Labs Inc.GlobeNewswire
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business UpdateGlobeNewswire
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]Yahoo! Finance
ELAB
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- 11/13/24 - Form 8-K
- ELAB's page on the SEC website